These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 25326473

  • 41. C3 glomerulopathy and current dilemmas.
    Ito N, Ohashi R, Nagata M.
    Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
    [Abstract] [Full Text] [Related]

  • 42. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H.
    Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M.
    Nat Genet; 2002 Aug; 31(4):424-8. PubMed ID: 12091909
    [Abstract] [Full Text] [Related]

  • 43. Update on C3 Glomerulopathy.
    Wooden B, Nester CM, Bomback AS.
    Adv Kidney Dis Health; 2024 May; 31(3):223-233. PubMed ID: 39004462
    [Abstract] [Full Text] [Related]

  • 44. C3d fragment of complement interacts with laminin and binds to basement membranes of glomerulus and trophoblast.
    Leivo I, Engvall E.
    J Cell Biol; 1986 Sep; 103(3):1091-100. PubMed ID: 3488995
    [Abstract] [Full Text] [Related]

  • 45. An update to the pathogenesis for monoclonal gammopathy of renal significance.
    Zuo C, Zhu Y, Xu G.
    Ann Hematol; 2020 Apr; 99(4):703-714. PubMed ID: 32103323
    [Abstract] [Full Text] [Related]

  • 46. Dense deposit disease in a child with febrile sore throat.
    Conti G, De Vivo D, Vitale A, Fede C, Santoro D.
    Saudi J Kidney Dis Transpl; 2017 Apr; 28(4):925-928. PubMed ID: 28748900
    [Abstract] [Full Text] [Related]

  • 47. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.
    Zhang Y, Nester CM, Holanda DG, Marsh HC, Hammond RA, Thomas LJ, Meyer NC, Hunsicker LG, Sethi S, Smith RJ.
    J Am Soc Nephrol; 2013 Nov; 24(11):1820-9. PubMed ID: 23907509
    [Abstract] [Full Text] [Related]

  • 48. Complement inhibitors for kidney disease.
    Wooden B, Tarragon B, Navarro-Torres M, Bomback AS.
    Nephrol Dial Transplant; 2023 Nov 08; 38(Supplement_2):ii29-ii39. PubMed ID: 37218685
    [Abstract] [Full Text] [Related]

  • 49. Toward a working definition of C3 glomerulopathy by immunofluorescence.
    Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, D'Agati VD.
    Kidney Int; 2014 Feb 08; 85(2):450-6. PubMed ID: 24067430
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. C3 dependent, C5 independent immune complex glomerulopathy in the mouse.
    Sawtell NM, Hartman AL, Weiss MA, Pesce AJ, Michael JG.
    Lab Invest; 1988 Mar 08; 58(3):287-93. PubMed ID: 2964544
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases.
    Meuleman MS, Grunenwald A, Chauvet S.
    Semin Immunol; 2022 Mar 08; 60():101634. PubMed ID: 35817659
    [Abstract] [Full Text] [Related]

  • 56. A Systematic Investigation on Complement Pathway Activation in Diabetic Retinopathy.
    Shahulhameed S, Vishwakarma S, Chhablani J, Tyagi M, Pappuru RR, Jakati S, Chakrabarti S, Kaur I.
    Front Immunol; 2020 Mar 08; 11():154. PubMed ID: 32117292
    [Abstract] [Full Text] [Related]

  • 57. Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy.
    Meuleman MS, Petitprez F, Pickering MC, Le Quintrec M, Artero MR, Duval A, Rabant M, Gilmore A, Boyer O, Hogan J, Servais A, Provot F, Gnemmi V, Eloudzeri M, Grunenwald A, Buob D, Boffa JJ, Moktefi A, Audard V, Goujon JM, Bridoux F, Thervet E, Karras A, Roumenina LT, Frémeaux Bacchi V, Duong Van Huyen JP, Chauvet S.
    J Am Soc Nephrol; 2024 Aug 01; 35(8):1034-1044. PubMed ID: 38709564
    [Abstract] [Full Text] [Related]

  • 58. Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis.
    Kiss MG, Papac-Miličević N, Porsch F, Tsiantoulas D, Hendrikx T, Takaoka M, Dinh HQ, Narzt MS, Göderle L, Ozsvár-Kozma M, Schuster M, Fortelny N, Hladik A, Knapp S, Gruber F, Pickering MC, Bock C, Swirski FK, Ley K, Zernecke A, Cochain C, Kemper C, Mallat Z, Binder CJ.
    Immunity; 2023 Aug 08; 56(8):1809-1824.e10. PubMed ID: 37499656
    [Abstract] [Full Text] [Related]

  • 59. The complement factor H-related proteins.
    Medjeral-Thomas N, Pickering MC.
    Immunol Rev; 2016 Nov 08; 274(1):191-201. PubMed ID: 27782332
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.